AMAZFIT
2.2.2024 15:58:27 CET | Business Wire | Press release
Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), a health technology company, has today announced its groundbreaking partnership with Kelvin Kiptum, the men's marathon world record holder and only athlete to complete a marathon in under two hours and one minute. As Amazfit’s ambassador, Kiptum will utilize the Amazfit Cheetah Pro to manage training and races, and the Amazfit Helio Ring to optimize recovery, ahead of marathon races in Rotterdam and Paris.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240201514405/en/
Amazfit ambassador Kelvin Kiptum set to break marathon world record (Graphic: Business Wire)
Zepp Health expressed enthusiasm for this dynamic partnership. Pengtao Yu, VP of Industrial Design, Brand & Consumer Marketing, stated: "We are thrilled about the collaboration between Amazfit and Kelvin Kiptum. As a health technology company, we are proud to support Kelvin's quest to break records and inspire individuals worldwide to pursue their own health and fitness goals. This partnership is a testament to our commitment to empowering people to lead healthier lives through intelligent healthcare fitness solutions."
Kelvin's recent marathon achievement in Chicago, clocking a remarkable 2:00:35, sets the stage for an extraordinary collaboration. Conquering recent marathons in Valencia and London, the 24-year-old runner aims to shatter the 2-hour mark in Rotterdam this April, and clinch gold at the 2024 Olympics in Paris.
To aid his preparation, Kelvin will wear Amazfit’s Cheetah Pro. This specialist running watch features MaxTrack™ dual-band circularly-polarized GPS antenna, with 99.5% the accuracy of a professional GPS locator, along with the innovative Zepp Coach™ - an AI solution generating tailored plans for athletes looking for optimal marathon preparation. This cutting-edge technology will support Kelvin as he hones the finer details of his training.
Kelvin Kiptum shares his excitement about the collaboration, stating, "Teaming up with Amazfit for this groundbreaking journey is truly exciting. The Amazfit Cheetah Pro has become an integral part of my training regimen. As I aim to break the 2-hour mark in Rotterdam and pursue gold at the Paris Olympics, I am confident that Amazfit will be my ultimate ally in pushing the limits of human potential. Together, we are set to redefine what's possible."
This partnership extends beyond the track, with Kiptum also utilizing recently-announced Amazfit Helio Ring to take control of his recovery, with in-depth analysis of sleep quality, mental and physical Readiness, and emotional state enabled by the smart ring's BioTracker™ and EDA sensors.
The symbiosis between Amazfit and Kelvin Kiptum is emblematic of a shared commitment to breaking limits. Just as the brand's smartwatch and smart-ring are crafted for athletes seeking to push boundaries with the support of cutting-edge technology, Kelvin Kiptum continuously exemplifies the limitless potential of human ability.
By forging strategic partnerships with elite athletes like Kelvin Kiptum, Amazfit aims to create a platform that transcends geographical boundaries, providing valuable insights into performance, training, and endurance for aspiring and professional athletes.
The Amazfit Cheetah Pro is available at Amazfit.com and select retailers worldwide. The Amazfit Helio ring will be released later this spring.
For more information, visit https://www.amazfit.com/en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201514405/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom